| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥8.21 |
| 52 Week High | CN¥14.40 |
| 52 Week Low | CN¥6.71 |
| Beta | 0.38 |
| 11 Month Change | 2.24% |
| 3 Month Change | -11.24% |
| 1 Year Change | -14.75% |
| 33 Year Change | -5.31% |
| 5 Year Change | 13.87% |
| Change since IPO | -17.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 600513 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | 1.2% | 1.0% | -1.4% |
| 1Y | -14.7% | -15.1% | -18.4% |
Return vs Industry: 600513 matched the CN Pharmaceuticals industry which returned -15.1% over the past year.
Return vs Market: 600513 exceeded the CN Market which returned -18.4% over the past year.
Price Volatility
| 600513 volatility | |
|---|---|
| 600513 Average Weekly Movement | 4.8% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in CN Market | 10.0% |
| 10% least volatile stocks in CN Market | 4.2% |
Stable Share Price: 600513 has not had significant price volatility in the past 3 months.
Volatility Over Time: 600513's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,296 | Ben Niu | www.lhpharma.com |
Jiangsu Lianhuan Pharmaceutical Co., Ltd. manufactures and sells pharmaceuticals, preparations, and API products in China. The company offers clopidogrel bisulfate tablets used to prevent atherothrombotic events; azithromycin tablets for the treatment of mild to moderate infections caused by susceptible strains of designated microorganisms; milrinone injection for short-term intravenous therapy in patients with acute compensated heart failure; and dapoxetine hydrochloride tablets for the treatment of premature ejaculation in men, as well as epulet, ebastine, felodipine, and terfenadine tablets, drotaverine hydrochloride injection, and danazol suppository. It also offers preparation products, which covers urinary system, antihistamines, cardiovascular drugs, steroid hormones, and antibiotics.
Jiangsu Lianhuan Pharmaceutical Co., Ltd. Fundamentals Summary
| 600513 fundamental statistics | |
|---|---|
| Market cap | CN¥2.34b |
| Earnings (TTM) | CN¥136.43m |
| Revenue (TTM) | CN¥2.25b |
17.2x
P/E Ratio1.0x
P/S RatioIs 600513 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 600513 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.25b |
| Cost of Revenue | CN¥1.16b |
| Gross Profit | CN¥1.09b |
| Other Expenses | CN¥952.05m |
| Earnings | CN¥136.43m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 30, 2024
| Earnings per share (EPS) | 0.48 |
| Gross Margin | 48.36% |
| Net Profit Margin | 6.06% |
| Debt/Equity Ratio | 46.4% |
How did 600513 perform over the long term?
See historical performance and comparison